New valvular heart disease guidelines recognise expanding role of TAVI
Ngày 19/12/2020 12:22 | Lượt xem: 105

New joint clinical practice guidelines on the treatment of patients with valvular heart disease have been issued today by the American College of Cardiology (ACC) and the American Heart Association (AHA). The 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease were published in the AHA’s journal Circulation and in the Journal of the American College of Cardiology.

The new clinical guidelines aim to provide evidence-based recommendations to optimise care and management of patients with valvular heart disease, and replace the 2014 guidelines and a focused update from 2017.

In particular the 2020 updated guidelines highlight the expanding indications for transcatheter valve implantation (TAVI), as a result of multiple randomised controlled trials comparing TAVI and surgical aortic valve replacement. The guidelines state: “The choice of type of intervention for a patient with severe aortic stenosis should be a shared decision-making process that considers the lifetime risks and benefits associated with type of valve (mechanical versus bioprosthetic) and type of approach (transcatheter versus surgical).”

Catherine Otto, co-chair of the guideline writing committee, and director of the Heart Valve Clinic at the University of Washington School of Medicine, Seattle, USA, commented: “Current research and new technology continue to transform the treatment of heart valve disease, as updated lifestyle and medication guidance evolve, and less invasive procedures have replaced traditional surgery for many patients.”

AHA and ACC add that treatment of valve regurgitation has improved thanks to more durable treatment options and lower risks surrounding procedures to repair or replace the valve involved.

The writing committee notes that the optimal timing of intervention for stenosis or regurgitation issues depends on the severity of the valve condition, as well as the safety and long-term effectiveness of treatment options. As ongoing clinical research data evolves, the recommended timing of interventions will shift to earlier in the disease course for some patients.

Additionally, the committee notes there are limitations in the research used for some areas of the guideline due to the small numbers of patients with specific types of valvular heart disease. More disease-specific studies and patient-centered trials that focus on each stage of the disease process are recommended.

Patients who have severe valvular heart disease and are being considered for valve repair or replacement should be evaluated by a specialised team working with a primary or comprehensive valve centre. A comprehensive valve centre (Level I) has the resources and capabilities to perform a full range of interventional and surgical valve procedures. A primary valve centre (Level II) can perform TAVI and more limited surgical procedures.

“Clinical studies over the past decade have increased awareness of the prevalence and importance of valvular heart disease in contributing to excess mortality, morbidity and a reduced quality of life, particular in older people,” said Otto. “Simultaneously, clinical studies have demonstrated the safety and effectiveness of new, less-invasive approaches for treatment of heart valve dysfunction. Integration of this expanded evidence base, in conjunction with expert clinical experience, will furnish both providers and patients with the guidance needed to ensure optimal outcomes for patients with heart valve conditions.”

In developing the recommendations, the writing committee used evidence-based methodologies based on an extensive review of available data through March 1, 2020. The review focused on trials, studies, registries, systematic reviews and expert opinion.

“There is a knowledge explosion in medicine today, which can overwhelm the clinician,” said Rick A. Nishimura, co-chair of the writing committee and the Judd and Mary Morris Leighton Professor of Cardiovascular Diseases at the Mayo Clinic in Rochester, USA. “This is particularly true in the area of valvular heart disease, in which multiple investigational trials are being rapidly performed and released, so that it becomes extremely difficult for an individual clinician to keep up with optimal treatments for each specific patient. The Valvular Heart Disease Guideline brings together experts in the field who review all the data and arrive at a consensus opinion for best treatment, outlined in the Class Recommendations.”

“While this guideline focuses on patients with end-stage heart valve disease,” said Otto. “Future research will also lead to treatments to prevent heart valve disease or earlier interventions to slow its progression.”

This guideline was developed in collaboration with and endorsed by the American Association for Thoracic Surgery, the American Society of Echocardiography, the Society for Cardiovascular Angiography and Interventions, the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons.

Print Chia sẽ qua facebook bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua google bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua twitter bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua MySpace bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua LinkedIn bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua stumbleupon bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua icio bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua digg bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua yahoo bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua yahoo bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua yahoo bài: New valvular heart disease guidelines recognise expanding role of TAVI Chia sẽ qua yahoo bài: New valvular heart disease guidelines recognise expanding role of TAVI

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP